H1N1 Vaccines Strategic Research Report 2024: Increasing Influenza Outbreaks and Viral Mutations Accelerates Demand - Global Market Forecast to 2030


Dublin, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The "H1N1 Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The global market for H1N1 Vaccines is estimated at US$2.2 Billion in 2023 and is projected to reach US$3.2 Billion by 2030, growing at a CAGR of 5.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.



The growth in the H1N1 vaccines market is driven by several factors, including increasing awareness of the importance of vaccination, government initiatives and funding, and technological advancements in vaccine development. Public health campaigns emphasizing the benefits of vaccination have significantly increased vaccine uptake. Government programs and policies that provide funding and resources for vaccine research, development, and distribution also play a pivotal role in market growth. Technological advancements in biotechnology and immunology have led to the development of more effective and safer vaccines.

Additionally, the rising prevalence of influenza outbreaks and the continuous mutation of the H1N1 virus drive the need for ongoing vaccination efforts. Collaboration between pharmaceutical companies and research institutions accelerates the innovation and availability of vaccines. The expansion of global healthcare infrastructure and improvements in cold chain logistics further support the widespread distribution and accessibility of H1N1 vaccines. Overall, these factors collectively contribute to the robust growth and development of the H1N1 vaccines market.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Intramuscular Vaccines segment, which is expected to reach US$1.1 Billion by 2030 with a CAGR of a 6.5%. The Intranasal Vaccines segment is also set to grow at 5.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $572.6 Million in 2023, and China, forecasted to grow at an impressive 8.5% CAGR to reach $734.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Abbott Laboratories, Inc., Baxter International, Inc., Cipla Ltd., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Key Attributes:

Report AttributeDetails
No. of Pages268
Forecast Period2023 - 2030
Estimated Market Value (USD) in 2023$2.2 Billion
Forecasted Market Value (USD) by 2030$3.2 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal


MARKET OVERVIEW

  • Influencer Market Insights
  • Global Economic Update
  • H1N1 Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

MARKET TRENDS & DRIVERS

  • Rising Awareness of Vaccination Importance Throws the Spotlight on H1N1 Vaccines
  • Government Initiatives and Funding Propel Growth in Vaccine Research and Development
  • Technological Advancements in Biotechnology Expands Addressable Market Opportunity
  • Enhanced Surveillance Systems Strengthens Business Case for Timely Vaccine Updates
  • Integration of Adjuvant Technology Generates Demand for More Effective Vaccines
  • Development of Cell-Based and Recombinant DNA Technologies Drives Adoption of Modern Manufacturing Methods
  • Increasing Influenza Outbreaks and Viral Mutations Accelerates Demand for H1N1 Vaccines
  • Digital Health Tools and EHRs Spur Growth in Vaccination Program Management
  • Improvements in Cold Chain Logistics Sustains Growth in Vaccine Accessibility
  • Public Health Campaigns and Education Programs Generates Awareness and Vaccine Uptake
  • Ongoing Research in Immunology and Virology Expands Addressable Market Opportunity for Advanced Vaccines
  • Impact of Seasonal Variability on Vaccination Needs
  • Safety and Efficacy Improvements in Vaccine Formulations Drives Adoption of New Vaccines

FOCUS ON SELECT PLAYERS (Total 33 Featured)

  • Abbott Laboratories, Inc.
  • Baxter International, Inc.
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/ijun5k

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

 
Global H1N1 Vaccines Market

Contact Data